BiVictriX Therapeutics, led by 33-year-old CEO Tiffany Thorn, is trying to fix one of the longest-standing problems in cancer treatment. The firm had raised £2.3 million in investment, including a significant slice from The Development Bank of Wales, before Thorn took the decision to list the BioTech business on the London Stock Exchange’s alternative AIM … Continue reading Could listed BiVictriX Therapeutics deliver cancer breakthrough?